FI65912C - Foerfarande foer framstaellning av farmaceutiskt anvaendbara inklusionskomplexer av prostacyklin och prostacyklin-c1-4-estrar med beta-cyklodextrin - Google Patents

Foerfarande foer framstaellning av farmaceutiskt anvaendbara inklusionskomplexer av prostacyklin och prostacyklin-c1-4-estrar med beta-cyklodextrin Download PDF

Info

Publication number
FI65912C
FI65912C FI782878A FI782878A FI65912C FI 65912 C FI65912 C FI 65912C FI 782878 A FI782878 A FI 782878A FI 782878 A FI782878 A FI 782878A FI 65912 C FI65912 C FI 65912C
Authority
FI
Finland
Prior art keywords
prostacyclin
cyclodextrin
solution
prostacyklin
complex
Prior art date
Application number
FI782878A
Other languages
English (en)
Finnish (fi)
Other versions
FI782878A (fi
FI65912B (fi
Inventor
Jozef Szejtli
Nee Rengei Magdolna Szejtli
Gyoergy Cseh
Istvan Stadler
Original Assignee
Chinoin Gyogyszer Es Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Gyogyszer Es Vegyeszet filed Critical Chinoin Gyogyszer Es Vegyeszet
Publication of FI782878A publication Critical patent/FI782878A/fi
Application granted granted Critical
Publication of FI65912B publication Critical patent/FI65912B/fi
Publication of FI65912C publication Critical patent/FI65912C/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C07D307/937Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI782878A 1977-09-23 1978-09-21 Foerfarande foer framstaellning av farmaceutiskt anvaendbara inklusionskomplexer av prostacyklin och prostacyklin-c1-4-estrar med beta-cyklodextrin FI65912C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUCI001770 1977-09-23
HU77CI1770A HU179141B (ru) 1977-09-23 1977-09-23

Publications (3)

Publication Number Publication Date
FI782878A FI782878A (fi) 1979-03-24
FI65912B FI65912B (fi) 1984-04-30
FI65912C true FI65912C (fi) 1984-08-10

Family

ID=10994670

Family Applications (1)

Application Number Title Priority Date Filing Date
FI782878A FI65912C (fi) 1977-09-23 1978-09-21 Foerfarande foer framstaellning av farmaceutiskt anvaendbara inklusionskomplexer av prostacyklin och prostacyklin-c1-4-estrar med beta-cyklodextrin

Country Status (20)

Country Link
JP (1) JPS5456685A (ru)
AT (1) AT369362B (ru)
BE (1) BE870646A (ru)
CH (1) CH637388A5 (ru)
CS (1) CS200242B2 (ru)
DD (1) DD138600A5 (ru)
DE (1) DE2840142A1 (ru)
DK (1) DK420778A (ru)
FI (1) FI65912C (ru)
FR (1) FR2404006A1 (ru)
GB (1) GB2006193B (ru)
GR (1) GR65001B (ru)
HU (1) HU179141B (ru)
IL (1) IL55569A (ru)
IT (1) IT1160661B (ru)
NL (1) NL7809643A (ru)
PL (1) PL121664B1 (ru)
SE (1) SE447574B (ru)
SU (1) SU847914A3 (ru)
YU (1) YU220678A (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53136513A (en) * 1977-05-06 1978-11-29 Ono Pharmaceut Co Ltd Stabilization of prostaglandin-x-related compounds
US4352793A (en) * 1979-04-26 1982-10-05 Sumitomo Chemical Company, Limited Pharmaceutical composition comprising bencyclane fumarate and cyclodextrin
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
JPS61289034A (ja) * 1985-06-17 1986-12-19 Teijin Ltd イソカルバサイクリン類脂肪乳剤
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
DE3740838A1 (de) * 1987-11-27 1989-06-08 Schering Ag Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel
WO2005073223A1 (ja) 2004-01-29 2005-08-11 Eisai R & D Management Co., Ltd. マクロライド系化合物の安定化方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (ru) * 1970-06-10 1975-02-04
US3953435A (en) * 1974-01-10 1976-04-27 Ono Pharmaceutical Company Aldehyde derivatives of prostaglandins
JPS5395958A (en) * 1977-01-31 1978-08-22 Ono Pharmaceut Co Ltd Prostaglandin analogues and process for their preparation
US4178367A (en) * 1977-02-21 1979-12-11 Ono Pharmaceutical Co. Ltd. Prostaglandin I2 analogues
JPS53136513A (en) * 1977-05-06 1978-11-29 Ono Pharmaceut Co Ltd Stabilization of prostaglandin-x-related compounds

Also Published As

Publication number Publication date
GB2006193A (en) 1979-05-02
YU220678A (en) 1983-10-31
PL121664B1 (en) 1982-05-31
CH637388A5 (de) 1983-07-29
BE870646A (fr) 1979-01-15
JPS5456685A (en) 1979-05-07
HU179141B (ru) 1982-08-28
IT7869160A0 (it) 1978-09-19
DD138600A5 (de) 1979-11-14
FI782878A (fi) 1979-03-24
SE447574B (sv) 1986-11-24
ATA677478A (de) 1982-05-15
AT369362B (de) 1982-12-27
SE7809946L (sv) 1979-03-24
DK420778A (da) 1979-03-24
NL7809643A (nl) 1979-03-27
SU847914A3 (ru) 1981-07-15
FR2404006A1 (fr) 1979-04-20
GR65001B (en) 1980-06-12
FI65912B (fi) 1984-04-30
IT1160661B (it) 1987-03-11
FR2404006B1 (ru) 1981-07-31
PL209773A1 (pl) 1979-06-04
IL55569A (en) 1981-12-31
CS200242B2 (en) 1980-08-29
DE2840142A1 (de) 1979-04-05
IL55569A0 (en) 1978-12-17
GB2006193B (en) 1982-05-26

Similar Documents

Publication Publication Date Title
SU1175350A3 (ru) Способ получени средства,тормоз щего воспалительные процессы
Fitzgerald et al. The effects of organic nitrates on prostacyclin biosynthesis and platelet function in humans.
EP0244832B1 (de) Ungesättigte Fettsäuren enthaltende Zubereitungen für die Synthese von Prostaglandinen und Hydroxyfettsäuren in biologischen Systemen
SK148496A3 (en) Pharmaceutical composition containing duocarmycin derivatives and method for stabilizing duocarmycin derivatives
FI67390B (fi) Foerfarande foer framstaellning av en inklusionskomplex av n-(1-fenyletyl)-3,3-difenylpropylamin eller dess hydroklorid me cyklodextrin
US4310543A (en) Prostaglandin compositions
US4036954A (en) Stable prostaglandin E group-containing formulation
FI65912C (fi) Foerfarande foer framstaellning av farmaceutiskt anvaendbara inklusionskomplexer av prostacyklin och prostacyklin-c1-4-estrar med beta-cyklodextrin
US4312866A (en) Use of rifamycin SV and its related salts in the treatment of rheumatoid arthritis, and related formulations suited for the purpose
US4623641A (en) Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes
KR100515201B1 (ko) 라세미화반응에대하여안정화된실란세트론제제
EP1618894B1 (en) Composition for injection
US4092428A (en) Process of preparing stable prostaglandin E group-containing formulation
EP0159777A1 (en) Stabilized 4-carbamoyl-imidazolium-5-olate
KR100247441B1 (ko) 트롬복산 레벨 억제용 경피투여 약제학적 아스피린 조성물
US4675182A (en) Complexes of prostaglandins
US4968673A (en) Use of a thromboxane receptor antagonist in renal diseases and dysfunction
JPH07157431A (ja) 安定なプロスタグランジンe製剤
JPS61171421A (ja) 安定なプロスタグランジンe類製剤の製造方法
JP3247695B2 (ja) エタノール摂取を妨げるチオカルバメートスルホキシド組成物
Jungbluth et al. Factors affecting ceftriaxone plasma protein binding during open heart surgery
US3749781A (en) Pharmaceutical composition and method of treatment
US4271150A (en) Urokinase preparation for oral administration
Baumann et al. (+)-Cyanidanol-3 as inhibitor of prostaglandin synthetase: Studies on renal medulla and liver of the rat in vitro and in vivo
GB2105988A (en) Anti-platelet aggregation dipyridamole with Al aspirin

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: CHINOIN GYOGUSZER ES VEGYESZETI TERMEKEK